Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3079679
Reference Type
Journal Article
Subtype
Review
Title
Lung cancer in never smokers: a review
Author(s)
Subramanian, J; Govindan, R
Year
2007
Is Peer Reviewed?
Yes
Journal
Journal of Clinical Oncology
ISSN:
0732-183X
EISSN:
1527-7755
Volume
25
Issue
5
Page Numbers
561-570
Language
English
PMID
17290066
DOI
10.1200/JCO.2006.06.8015
Web of Science Id
WOS:000244176000016
Abstract
Lung cancer is the leading cause of cancer-related death in the United States. Although tobacco smoking accounts for the majority of lung cancer, approximately 10% of patients with lung cancer in the United States are lifelong never smokers. Lung cancer in the never smokers (LCINS) affects women disproportionately more often than men. Only limited data are available on the etiopathogenesis, molecular abnormalities, and prognosis of LCINS. Several etiologic factors have been proposed for the development of LCINS, including exposure to radon, cooking fumes, asbestos, heavy metals, and environmental tobacco smoke, human papillomavirus infection, and inherited genetic susceptibility. However, the relative significance of these individual factors among different ethnic populations in the development of LCINS has not been well-characterized. Adenocarcinoma is the predominant histologic subtype reported with LCINS. Striking differences in response rates and outcomes are seen when patients with advanced non-small-cell lung cancer (NSCLC) who are lifelong never smokers are treated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors such as gefitinib or erlotinib compared with the outcomes with these agents in patients with tobacco-associated lung cancer. Interestingly, the activating mutations in the EGFR-TK inhibitors have been reported significantly more frequently in LCINS than in patients with tobacco-related NSCLC. This review will summarize available data on the epidemiology, risk factors, molecular genetics, management options, and outcomes of LCINS.
Keywords
Antineoplastic Agents; Environmental Pollutants; Hormones; Tumor Suppressor Protein p53; ErbB Receptors; EC 2.7.10.1; Index Medicus; Genetic Predisposition to Disease; Cooking; Risk Factors; Lung Diseases -- complications; Treatment Outcome; Tumor Suppressor Protein p53 -- genetics; Tumor Virus Infections -- complications; DNA Methylation; ErbB Receptors -- genetics; Environmental Pollutants -- adverse effects; Hormones -- metabolism; Chromosome Aberrations; Sex Factors; Sex Distribution; Mutation; Genes, ras; Smoking -- adverse effects; Lung Neoplasms -- genetics; Carcinoma, Non-Small-Cell Lung -- drug therapy; Adenocarcinoma -- metabolism; Carcinoma, Non-Small-Cell Lung -- genetics; Adenocarcinoma -- drug therapy; Lung Neoplasms -- drug therapy; Lung Neoplasms -- metabolism; Carcinoma, Non-Small-Cell Lung -- metabolism; Carcinoma, Non-Small-Cell Lung -- epidemiology; Carcinoma, Non-Small-Cell Lung -- etiology; Adenocarcinoma -- genetics; Adenocarcinoma -- epidemiology; Adenocarcinoma -- etiology; Lung Neoplasms -- epidemiology; Lung Neoplasms -- etiology
Tags
OPPT REs
•
OPPT_Asbestos, Part I: Chrysotile_F. Human Health
Total – title/abstract screening
On topic
Peer review
Secondary source/ Review
•
OPPT_Asbestos, Part I: Chrysotile_Supplemental Search
LitSearch: Sept 2020 (Undated)
ProQuest
PubMed
Toxline
WoS
Legacy Uses
Health Outcomes
Exposure
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity